SCHEMBL3450247

SCHEMBL3450247

CCOC(=O)c1cncc(-c2cnc(Nc3cccc(C(N)=O)c3)nc2-n2ccc(C(F)(F)F)n2)c1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SYK P43405 5/20 0.51
AURKA O14965 2/20 0.42
KDM4E B2RXH2 2/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
NPC1 O15118 1/20 0.41
RAB9A P51151 1/20 0.41
TYK2 P29597 3/20 0.41
JAK1 P23458 2/20 0.41
FGFR1 P11362 1/20 0.41
JAK2 O60674 1/20 0.38
JAK3 P52333 1/20 0.38
MEN1 O00255 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
HPGD P15428 1/20 0.38
HTT P42858 1/20 0.38
UBE2N P61088 1/20 0.38
KMT2A Q03164 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3448083 0.93 SYK (0.51) SYKKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3451287 0.92 SYK (0.51) SYKKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3450291 0.91 SYK (0.50) SYKKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3450518 0.91 SYK (0.49) SYKKDM4ETYK2JAK1FGFR1
SCHEMBL3449544 0.89 SYK (0.48) SYKTYK2JAK1FGFR1JAK2
SCHEMBL3450697 0.89 SYK (0.49) SYKAURKAJAK3
SCHEMBL3448893 0.89 SYK (0.48) SYKKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL13311923 0.89 SYK (0.48) SYKKDM4ESMN1; SMN2NPC1RAB9A
SCHEMBL3447139 0.88 SYK (0.51) SYKAURKAKDM4ESMN1; SMN2NPC1
SCHEMBL3448166 0.88 SYK (0.45) SYKNPC1TYK2JAK1JAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF ASTRAZENECA AB 2010-06-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100137313-A1 HETEROCYCLIC DERIVATIVES AND METHODS OF USE THEREOF SDHA, SDHB, UROD SYK 804/4885AURKA 3990/4885KDM4E 3882/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.